Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2024BMJ OpenOpen Access

Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non-valvular atrial fibrillation: protocol for a prospective, randomised, open-label, blinded endpoint trial (APIDP2)

View Full Paper
Ask AI
Bookmark
Share

Authors

MFMaxence FicheuxLPLaure Peyro‐Saint‐PaulDBDorothée Balayn

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ficheux et al. (2024) studied this question.

synapsesocial.com/papers/68e59d93b6db643587538200https://doi.org/10.1136/bmjopen-2024-089353
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study2018 · 38 citations
  2. 2Safety and Effectiveness of Apixaban Versus Warfarin in Peritoneal Dialysis Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation2026
  3. 3Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial2022 · 235 citations
  4. 4Safety and Efficacy of Apixaban Use in Peritoneal Dialysis: A Review of the Literature2021 · 8 citations
  5. 5Pharmacokinetics of Apixaban Among Peritoneal Dialysis Patients2023 · 9 citations